Overview

• Researchers have identified a genetic variant in the fibronectin gene that lowers the risk of developing Alzheimer's by up to 70%.
• This variant, found in a small percentage of APOEe4 carriers, delays the onset of Alzheimer's by approximately four years.
• The discovery indicates that excess fibronectin at the blood-brain barrier may hinder amyloid clearance, a key factor in Alzheimer's pathology.
• Studies suggest that targeting fibronectin could be a promising approach for new Alzheimer's therapies, potentially benefiting a broad population.
• The findings have been validated by independent studies, boosting confidence in the potential for these new therapeutic avenues.